BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Aug 30, 2018
Tools & Techniques

Master of autism

The discovery of a master regulator of autism risk genes has yielded the first mouse model of the form of the condition that accounts for about 90% of patients, and could spark a new way...
BioCentury | Mar 19, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-455-5p (miR-455-5p); adenosine deaminase RNA-specific (ADAR; ADAR1)

...the tumor suppressor cytoplasmic polyadenylation element binding protein 1 (CPEB1) . In human melanoma cell lines, over-expression of wild-type miR-455-5p decreased CPEB1...
BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Neurology

...Licensing status Publication and contact information Neurology Fragile X syndrome Cytoplasmic polyadenylation element binding protein 1 (CPEB1) Mouse studies suggest inhibiting CPEB1...
...help treat fragile X syndrome. In a mouse model of fragile X syndrome, knockout of Cpeb1...
...normal protein translation and increased synaptic plasticity compared with no knockout. In the mouse model, Cpeb1...
Items per page:
1 - 4 of 4